secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0000950170-22-002728
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors
-------------------------------------------------------------------------

- Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.
- Received option to purchase 30,000 shares at $1.49/share, vesting in 36 monthly installments.
- Entitled to $40,000 annual retainer plus annual option grants for service as director.
- His expertise expected to advance CLS-AX (axitinib) for wet AMD and SCS platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/0000950170-22-002728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/clsd-20220303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer